zipMoney

From butchers paper to the cloud, zipMoney proprietarily developed a digital credit and payments engine to facilitate point of sale financial transactions. In our formative years, R&D Capital Partners was pivotal in supporting our accelerated growth. Their deep understanding of our model and R&D activities, allowed R&DCP to turn around an expedited funding solution that met out capital needs and bridged us to the end of year full refund. By utilising R&DCP together with our seed investors, zipMoney was able to prove out its business model, before raising equity and debt from traditional markets leading to a successful listing on the Australian Stock Exchange in September 2015.

Larry Diamond – Director – zipMoney Payments Pty Ltd

 

Truscreen

Truscreen specialises in the R&D and commercialisation of technologies for real time identification of cancerous tissue.  R&D Capital Partners’  innovative funding solution allowed us to extend our R&D program without having to raise additional equity to fund our China Food and Drug Administration approval in April 2015.  With this significant milestone achieved, we were then able to raise $5 million in fresh equity in June 2015 at $0.25c per share representing a 50% increase over the price of $0.16 per share prior to the involvement of R&D Capital Partners.

Martin Dillon – Chief Executive Officer – TruScreen Pty Ltd

 

Botanical Innovations

I would like to thank the team at R&D Capital Partners in conjunction with TCF Services for all their help in providing a R&D Tax prepayment against our future R&D Tax benefit, in addition to the claim preparation and facilitating prompt payment from the ATO under the R&D Tax Incentive.  Botanical Innovations is a new company investing in the research, development and commercialisation of proprietary products. As a result the business is not able to secure working capital loans from traditional banks and financial institutions. The team at R&D Capital/ TCF Services understand the value of the R&D Tax Incentive which enabled us to secure a prepayment loan against our claim to assist with ongoing R&D funding. We found the service fast, efficient, value for money and professional. It was a pleasure doing business with the team and I would highly recommend using their services to anyone looking to access government funding.

Kerry Ferguson – Managing Director – General Industry Pty Ltd t/a Botanical Innovations

 

Minomic

Minomic is an immuno-oncology company developing “next-gen” cancer testing and immuno-therapeutics for global markets.  R&D Capital Partners’ understanding of our research activities avoided any delays in implementing their innovative loan package.  With their financial support in place we were able to undertake our various pilot trials in the US and are able to progress our planned human therapeutic trials utilising our proprietary technology.  The data from these trials has strengthened our intellectual property which, in turn, underpins our ability to raise new equity.  This new equity together with further loans from R&DCP will be used to commercialise our diagnostic test and fund further therapeutic development.

David Burdis – Chief Operations and Financial Officer – Minomic International Ltd